Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Xencor, Inc. (XNCR : NSDQ)

• Company Description    Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. Number of Employees: 260

• Price / Volume Information    Yesterday's Closing Price: $19.44 Daily Weekly Monthly 20 Day Moving Average: 1,070,801 shares Shares Outstanding: 74.14 (millions) Market Capitalization: $1,441.32 (millions) Beta: 0.86 52 Week High: $21.26 52 Week Low: $6.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 31.89% 30.92% 12 Week 62.95% 58.49% Year To Date 26.98% 17.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 465 NORTH HALSTEAD STREET SUITE 200 - PASADENA,CA 91107 USA ph: 626-305-5900 fax: 626-305-0350 investors@xencor.com http://www.xencor.com

• General Corporate Information    Officers Bassil I. Dahiyat - Chief Executive Officer; President and Director Bart Jan Cornelissen - Senior Vice President & Chief Financial Officer A. Bruce Montgomery - Director Kurt Gustafson - Director Kevin C. Gorman - Director Peer Information Xencor, Inc. (GSAC) Xencor, Inc. (CASIF) Xencor, Inc. (ALCD.) Xencor, Inc. (OMNN) Xencor, Inc. (CGPI.) Xencor, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98401F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 74.14 Most Recent Split Date: (:1) Beta: 0.86 Market Capitalization: $1,441.32 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.85 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.79 Price/Cash Flow: - Price / Sales: 14.80 EPS Growth vs. Year Ago Period: -159.09% vs. Previous Quarter: -1,800.00% Sales Growth vs. Year Ago Period: -86.20% vs. Previous Quarter: -84.01% ROE 06/30/26 - - 03/31/26 - -28.77 12/31/25 - -14.58 ROA 06/30/26 - - 03/31/26 - -20.52 12/31/25 - -10.42 Current Ratio 06/30/26 - - 03/31/26 - 6.57 12/31/25 - 6.25 Quick Ratio 06/30/26 - - 03/31/26 - 6.57 12/31/25 - 6.25 Operating Margin 06/30/26 - - 03/31/26 - -177.10 12/31/25 - -73.20 Net Margin 06/30/26 - - 03/31/26 - -177.10 12/31/25 - -73.20 Pre-Tax Margin 06/30/26 - - 03/31/26 - -174.61 12/31/25 - -71.38 Book Value 06/30/26 - - 03/31/26 - 6.96 12/31/25 - 8.90 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.12 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 10.74

Powered by Zacks Investment Research ©